(Total Views: 446)
Posted On: 11/01/2019 5:41:35 PM
Post# of 148870
I agree that there is substantial confusion.
One thing to remember is that NP has been very clear and vocal publicly that BP is not interested in COMBO. (I interpreted that to mean that GILD and ViiV are not interested in COMBO). Therefore, my understanding is that the licensing deal is with a Mid-Tier pharma company. NP used the term mid-tier in one of his public communications recently -- but it was unclear if he was referring to the HIV franchise or the non-HIV.
In contrast, NP has also been very clear that GILD and ViiV are both very interested in MONO. But that they will take a wait and see approach to the development.
So, unless GILD or ViiV have changed their posture after the licensing deal was announced, I'm inclined to believe it is a mid-tier pharma.
But then the question becomes, do you just license COMBO to mid-tier or do you include MONO? Ideally, you would partner with GILD or ViiV for MONO. It sounds like they would be ready to move shortly after P3 is initiated for MONO.
One thing to remember is that NP has been very clear and vocal publicly that BP is not interested in COMBO. (I interpreted that to mean that GILD and ViiV are not interested in COMBO). Therefore, my understanding is that the licensing deal is with a Mid-Tier pharma company. NP used the term mid-tier in one of his public communications recently -- but it was unclear if he was referring to the HIV franchise or the non-HIV.
In contrast, NP has also been very clear that GILD and ViiV are both very interested in MONO. But that they will take a wait and see approach to the development.
So, unless GILD or ViiV have changed their posture after the licensing deal was announced, I'm inclined to believe it is a mid-tier pharma.
But then the question becomes, do you just license COMBO to mid-tier or do you include MONO? Ideally, you would partner with GILD or ViiV for MONO. It sounds like they would be ready to move shortly after P3 is initiated for MONO.
(0)
(0)Scroll down for more posts ▼
